What's New
-
Real-life patient experience demonstrates the positive impact of pharmacogenetic (PGx) testing on patients suffering with pain and mental health conditions
Only one in three people prescribed antidepressants or pain medication find an effective treatment on the first try. Not finding the right medication can have dire consequences. The study recruited 50 patients being treated for chronic pain and mental health conditions. -
A partnership in innovation: Calian Group and Inagene Diagnostics partner to change the lives of Canadians suffering from mental health and pain conditions.
Calian Group Ltd., one of Canada's largest national health services organizations, supported a ground-breaking pilot study by Inagene Diagnostics in late 2020 to evaluate the “real-life” value of pharmacogenetic testing in optimizing the treatment of chronic pain and mental health conditions. Fifty Canadians who were being treated for chronic pain and concurrent mental health conditions were recruited from a busy clinic in PEI for the study in late 2020 to evaluate the impact pharmacogenetic testing could have on treatment, and on the time and cost burden involved in trialing different medications. The results were compelling and validated outcomes from previous studies.
-
Inagene Diagnostics Inc. & dnaPower Partnership
Inagene Diagnostics Inc is excited to announce a new partnership with dnaPower Inc., a fellow Canadian company, specializing in applying the power of genetics to help individuals make better, data driven decisions, about their health!
